Abstract Background Molecularly targeted therapies, such as monoclonal antibodies (mAbs) and Janus Kinase inhibitors (JAKis), have emerged as essential tools in the treatment of dermatological diseases. These therapies modulate the immune system through specific signaling pathways, providing effective alternatives to traditional systemic immunosuppressive agents. This review aims to provide an updated summary of targeted immune therapies for inflammatory skin diseases, considering their pathophysiology, efficacy, dosage, and safety profiles. Methods The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A systematic search was conducted on PubMed over the past 10 years, focusing on randomized clinical trials, case reports, and case series related to targeted immune therapies in dermatology. Eligibility criteria were applied, and data were extracted from each study, including citation data, study design, and results. Results We identified 1360 non-duplicate articles with the initial search strategy. Title and abstract review excluded 1150, while a full-text review excluded an additional 50 articles. The review included 143 studies published between 2012 and 2022, highlighting 39 drugs currently under investigation or in use for managing inflammatory skin diseases. Study limitations The heterogeneity of summarized information limits this review. Some recommendations originated from data from clinical trials, while others relied on retrospective analyses and small case series. Recommendations will likely be updated as new results emerge. Conclusion Targeted therapies have revolutionized the treatment of chronic skin diseases, offering new options for patients unresponsive to standard treatments. Paradoxical reactions are rarely observed. Further studies are needed to fully understand the mechanisms and nature of these therapies. Overall, targeted immune therapies in dermatology represent a promising development, significantly improving the quality of life for patients with chronic inflammatory skin diseases. mAbs (mAbs JAKis, JAKis , (JAKis) diseases pathways agents pathophysiology efficacy dosage profiles Metaanalyses Meta PRISMA (PRISMA guidelines 1 years trials reports applied design 136 nonduplicate non duplicate strategy 1150 fulltext full text 5 14 201 2022 3 emerge treatments observed Overall development (JAKis 13 115 20 202 11 2

ABSTRACT Objective: To determine the needs in relatives of critically ill patients of an IV level institution in Montería, Colombia. Methodology: Descriptive, cross-sectional research with a quantitative approach. For the collection of information, the Questionnaire of Needs of the Relatives of Intensive Care Patients and a sociodemographic data card were applied. Results: The needs that were determined were honest information regarding the state and progress of the patient and receive an explanation of the equipment being used. The dimension that presented the greatest needs was that of communication. Conclusions: The family of a person admitted to an intensive care service should be taken into account in the care process.

RESUMEN Objetivo: Determinar las necesidades en familiares de pacientes críticos de una institución de IV nivel en Montería, Colombia. Metodología: Investigación descriptiva, transversal con enfoque cuantitativo. Para la recolección de la información se aplicó el Cuestionario de Necesidades de los Familiares de Pacientes de Cuidados Intensivos y una cédula de datos sociodemográficos. Resultados: Las necesidades que se determinaron fueron la información sincera respecto al estado y progreso del paciente y recibir explicación del equipamiento que está utilizándose. La dimensión que presentó mayores necesidades fue la de comunicación. Conclusiones: El familiar de una persona ingresada en un servicio de cuidado intensivo debe ser tomado en cuenta en el proceso de atención.